YYZ Pharmatech Inc. announces residency at JLABS in Toronto

TORONTO — YYZ Pharmatech Inc. (YYZ), involved in plasma proteomics, announced that it has been accepted as a resident company of Johnson & Johnson’s global incubator network, JLABS in Toronto.

“We are beyond thrilled to join this prestigious community of innovators,” said Mike Badeau, President & COO of YYZ.

JLABS is a global network of open innovation ecosystems, enabling and empowering companies to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. JLABS tries to help entrepreneurs in pharmaceutical, medical device and health tech bring healthcare solutions to patients and consumers.

YYZ Pharmatech Inc. and John G. Marshall Ph.D., a professor at Toronto Metropolitan University (TMU), have specialized in the field of plasma proteomics in the past. Plasma is derived from blood and contains thousands of proteins and peptides, which can become important new biomarkers and medicines for a wide range of diseases.

While plasma is data-rich, it is also notoriously complex to work with, resulting in much of the plasma proteome remaining out of reach. YYZ says it has built a technology platform to discover, validate and measure even the most elusive low-abundance proteins and peptides from plasma.

“Our mission is to profoundly progress new medicines for patients by revealing and understanding important new biology from plasma at the lowest possible levels” said Badeau.

YYZ is a spinout from The Marshall Team in the Faculty of Science at TMU, an emergent contributor to the Toronto life science ecosystem.

“YYZ is a committed and thoughtful partner in supporting and championing the impactful research from the Marshall group. Their results will have international impact and it is not hyperbolic to say that once applied, these discoveries will save lives,” said David Cramb Ph.D., Dean, Faculty of Science, TMU.